STOCK TITAN
  1. Home
  2. SEC Filings
  3. VICR
  4. [144] VICOR CORP SEC Filing

VICR insider 10b5-1 sales list multiple June 2026 blocks

VICR reports proposed and recent scheduled equity sales.

Filing Impact
(Neutral)
Filing Sentiment

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment worksHow the balance works

Form Type
144

Rhea-AI Filing Summary

VICR reports proposed and recent scheduled equity sales. The filing lists multiple 10b5-1 sales attributed to Patrizio Vinciarelli with specific sale dates and share counts, including repeated 20,000‑share transactions in June 2026 and larger sale blocks reported across March–April 2026

Insights

Multiple scheduled insider sales via 10b5-1 plans are reported across March–June 2026.

The excerpt lists numerous dated transactions by Patrizio Vinciarelli, often in round lots (e.g., 20,000 shares) and several larger blocks in March–April 2026. These entries are presented as 10b5-1 sales rather than discretionary open‑market trades.

Cash‑flow treatment and aggregate proceeds are shown per trade as currency amounts; timing and methods are explicit by date. Subsequent filings will provide the full post‑transaction position if disclosed.

Scheduled sale 20,000 shares 06/16/2026 10b5-1 sale by Patrizio Vinciarelli
Proceeds (example) <money>$6,564,097.00</money> Proceeds reported for 20,000 shares sold on <date>06/16/2026</date>
Scheduled sale 20,000 shares 06/15/2026 10b5-1 sale by Patrizio Vinciarelli
Proceeds (example) <money>$6,372,972.00</money> Proceeds reported for 20,000 shares sold on <date>06/15/2026</date>
Large block sale 50,000 shares 04/15/2026 10b5-1 sale reported
Proceeds (example) <money>$9,660,511.00</money> Proceeds reported for 50,000 shares on <date>04/15/2026</date>
10b5-1 regulatory
"10b5-1 Sales for PATRIZIO VINCIARELLI 25 Frontage Road Andover"
A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.
Form 144 regulatory
"144: Securities Sold During The Past 3 Months"
Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.
Founders Shares market
"Common | 11/10/1981 | Founders Shares | Issuer"
Founders shares are a special block of a company’s stock originally given to the people who started the business; they often carry extra voting power or favorable terms compared with regular shares. For investors, these shares matter because they concentrate control and influence how future funding, ownership dilution, and decision-making will play out—think of founders shares as the steering wheel that can steer a company’s direction even as more passengers (investors) climb aboard.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does VICR's Form 144 show about recent insider activity?
The Form 144 lists multiple scheduled 10b5-1 sales by Patrizio Vinciarelli, specifying sale dates and share counts. It includes several 20,000‑share transactions in June 2026 and larger blocks reported in March–April 2026, with per‑trade proceeds noted.

Are the June 2026 transactions for VICR routine scheduled sales?
Yes. The June entries are identified as 10b5-1 sales, indicating they were executed under a prearranged plan. The filing lists multiple dated 20,000‑share entries in June 2026 and shows per‑trade dollar amounts for each sale.

Who is listed as the seller in these VICR transactions?
The filing attributes many sales to Patrizio Vinciarelli and also shows institutional entries for entities such as Brigham and Women's Hospital and Lahey Hospital & Medical Center on specific dates. Each row pairs a seller name, share count, date, and sale proceeds.

Does the filing disclose total shares outstanding or aggregate proceeds?
The excerpt provides per‑trade proceeds and individual share counts by date but does not present an aggregate total for all sales in the excerpt. Each transaction row pairs a share count with a currency amount and a specific sale date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Accepted by SEC EDGAR

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Source: View Original Filing on SEC EDGAR

Keep reading

More on VICR

All VICR news

Trending in the feed

LQDA
Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH Open the live feed